High-dosage ustekinumab for the treatment of severe hidradenitis suppurativa

Eur J Dermatol. 2019 Dec 1;29(6):659-661. doi: 10.1684/ejd.2019.3663.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adult
  • Dermatologic Agents / administration & dosage*
  • Female
  • Hidradenitis Suppurativa / drug therapy*
  • Humans
  • Male
  • Severity of Illness Index
  • Ustekinumab / adverse effects*

Substances

  • Dermatologic Agents
  • Ustekinumab